Skip to main content
Premium Trial:

Request an Annual Quote

Clarification: Jan 31, 2003

Premium

In the article detailing the wind-down of the Affymetrix and Agilent Technologies microarray scanner sales and distribution agreement published in the Jan. 10, 2003 edition of BioArray News, Ned Barnholt, the CEO of Agilent, said the company had concluded the arrangement. Agilent told BioArray last week that Agilent and Affymetrix have a scanner supply agreement in place through February 2003, and Affymetrix chose not to extend the agreement beyond that. There has been no agreement to end the contract early and “Agilent is honoring our obligations of the contract,” the company said.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.